Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.

NCT04178967 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04178967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04178967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
October 29, 2019
Completion date
April 28, 2022
Enrollment
445 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis